OncoMed Pharmaceuticals Commences Third Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Carboplatin and Paclitaxel in Ovarian Cancer

[GlobeNewswire] – REDWOOD CITY, Calif. — OncoMed Pharmaceuticals, Inc. , a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the initiation … more

View todays social media effects on OMED

View the latest stocks trending across Twitter. Click to view dashboard

See who OncoMed is hiring next, click here to view